THERAPY DOSSIER · th-6b098f7bd2c4

Gentiana asclepiadea L. methanol extracts of aerial parts (GAA) and roots (GAR)

Nutraceutical

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: GAA; GAR; willow gentian extract
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 23146698 ↗2012Reported benefit

Hepatoprotective effects of Gentiana asclepiadea L. extracts against carbon tetrachloride induced liver injury in rats.

RatChemical/toxinWistarmaleOral administration100, 200 and 400 mg/kg body weightOnce daily for 7 days before carbon tetrachloride challenge

Model: Acute liver injury induced by carbon tetrachloride in rats

Both extracts significantly reduced serum transaminases, alkaline phosphatase and bilirubin, raised total protein and antioxidant enzyme activities, lowered malondialdehyde and improved liver histopathology, with only slight genotoxic effects seen for the root extract.

Extraction: extract · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.

Loading the evidence…